Verastem (VSTM) Announces Earnings Results

Verastem (NASDAQ:VSTM) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01), Yahoo Finance reports.

Verastem (NASDAQ:VSTM) traded down $0.02 during trading on Wednesday, hitting $3.34. 243,246 shares of the stock traded hands, compared to its average volume of 676,561. The company has a market capitalization of $171.71, a PE ratio of -2.04 and a beta of 2.25. Verastem has a 52-week low of $1.37 and a 52-week high of $5.71. The company has a current ratio of 3.12, a quick ratio of 3.12 and a debt-to-equity ratio of 0.06.

How to Become a New Pot Stock Millionaire

A number of equities research analysts have issued reports on VSTM shares. Cantor Fitzgerald reissued a “buy” rating and set a $17.00 target price on shares of Verastem in a report on Wednesday, February 7th. Cann reissued a “buy” rating and set a $13.00 target price on shares of Verastem in a report on Friday, January 26th. Oppenheimer set a $13.00 target price on shares of Verastem and gave the company a “buy” rating in a report on Thursday, December 21st. HC Wainwright set a $10.00 target price on shares of Verastem and gave the company a “buy” rating in a report on Wednesday, December 13th. Finally, Raymond James Financial reissued a “buy” rating on shares of Verastem in a report on Monday, December 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. Verastem currently has a consensus rating of “Buy” and an average target price of $10.14.

An institutional investor recently raised its position in Verastem stock. Northern Trust Corp lifted its position in Verastem Inc (NASDAQ:VSTM) by 40.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 73,750 shares of the biopharmaceutical company’s stock after purchasing an additional 21,178 shares during the quarter. Northern Trust Corp owned about 0.20% of Verastem worth $160,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 33.22% of the company’s stock.

WARNING: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3262059/verastem-vstm-announces-earnings-results.html.

Verastem Company Profile

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Earnings History for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barclays Reaffirms Hold Rating for Webster Bank
Barclays Reaffirms Hold Rating for Webster Bank
Gazit Globe  and Getty Realty  Head to Head Survey
Gazit Globe and Getty Realty Head to Head Survey
RTI Surgical  & Coloplast  Critical Contrast
RTI Surgical & Coloplast Critical Contrast
Under Armour  versus Next  Head to Head Review
Under Armour versus Next Head to Head Review
Scientific Games Co.  Expected to Announce Earnings of -$0.24 Per Share
Scientific Games Co. Expected to Announce Earnings of -$0.24 Per Share
-$0.09 Earnings Per Share Expected for Pluristem Therapeutics Inc.  This Quarter
-$0.09 Earnings Per Share Expected for Pluristem Therapeutics Inc. This Quarter


© 2006-2018 Ticker Report. Google+.